Biocon Redefining Biological Equations Dr. KIRAN MAZUMDAR SHAW Dr.

Dr. Kiran Mazumdar Shaw was born on 23 March, 1953 in Bangalore. BSc in Zoology from Bangalore university in 1973. Masters in brewing from University of Ballart, Australia in 1974. Started working in Carlton & United Beverages in 1974 as a trainee. She joined Biocon Biochemicals Limited in Ireland in 1978, as Trainee Manager .

BIRTH OF BIOCON She founded Biocon India with a capital of Rs. 10,000/- in 1978. Started producing an digestive enzyme from papaya. All the banks rejected their loan applications. Company grew slowly Indias largest biopharmaceutical company Indias richest women- Rs. 2,100 crore.

Achievements by the MD Wharton Infosys Business Transformation Award (2006) Padma Bhushan (2005). The Economic Times Business Woman of the Year Award (2004) Whirlpool GR8 Women award for Science and Technology (2004) Ernst & Young Entrepreneur of the Year Award in Healthcare & Life Sciences Category (2002) Padma Shri (1989) Rotary award for the Best Model Employer (1983) Gold for Best Woman Entrepreneur , Institute of Marketing Management (1982)

Facts about BIOCON Biocon is India's first and largest biotechnology company First biotechnology company to export microbial enzymes to USA and Europe First biotechnology company to receive ISO 9001 certification in India The company ranks first in Asia in terms of revenues and market capitalisation and sixteenth globally.

Products of BIOCON Anti-Diabetic Agents Anti-Hypertensive Agents Anti-Inflammatory Agents Antioxidants Cardiovascular Agents Digestive Aid Enzymes Haemostatic Agents

Hepatoprotective Agents Immunosuppressants Nutraceuticals

Services of BIOCON Licensing Contract Manufacturing Research Services

Business BIOCON Split Business Technique (SBT) Divided their business into three subunits that are collaborative with each other and at the same time they are individual in operation. Syngene Clinigene Biocon

Syngene CLINIGENE Clinical Development Services- National level biological surveys Pre-Clinical Discovery Services- IPR, laboratory setups and molecular discovery.

BIOCON Commercialization Marketing for International health products

ADVANTAGES OF SBT Scope of R&D and manufacturing operations increases. Facilitates new product discovery. Provide multiple revenue streams to balance risk Driving more innovation Accelerate growth Facilitate the delivery of product in the time.

Subsidiary Companies Syngene International Limited Clinigene International Limited Biocon Biopharmaceuticals Private Limited (BBPL) AxiCorp BASED IN EUROPE NeoBiocon BASED IN ABU DHABI HRM in BIOCON Biocon employee approximately 3600 qualified personnel - from biologists, chemists, medical practitioners, pharmacologists, engineers, finance / legal / marketing analysts, HR generalists to general administrators. 15% of Biocon employees are women The average age of the employees is 29 years.

Departments Top mangment Middle level mangmnet HRM FINANCE MARKETING OPRATIONS IT R &D QA & QC Packaging Regulatory Affairs

Startergic Collabration BIOCON - MYLAN: 2009 BIOCON - ISB: 2009 SYNGENE DuPONT CROP PROTECTION: 2009 SYNGENE - SAPIENT DISCOVERY 2009

BIOCON-ABRAXIS: 2007 BIOCON- DEAKIN UNIVERSITY: 2007 SYNGENE- BRISTOL-MYERS SQUIBB: 2007 BIOCON- NEOPHARMA: 2007

Financial front The paid-up capital of Syngene as on March 31st, 2009 is Rs. 28,750,000. The paid-up capital of Clinigene as on March 31st, 2009 is Rs. 500,000 On December 31st 2008, the subscribed capital of AxiCorp is 116,000 The paid-up capital of BBPL as on March 31st, 2009 is Rs. 176,000,000 The paid up capital of NeoBiocon as on March 31st, 2009 is AED 300,000 SHARE PRICE - 228.95 (BSE)

Objective of the company To be an integrated biotechnology enterprise of global distinction. If you want India to become better then the best, let the BIOCON be your guest.

BIOCON INCEPTION - 1978 LARGEST BIOTECHNOLOGY ENTERPRISE 14 TH LARGEST BIOTECHNOLOGY COMPANY GLOBALLY $167 MILLION TURNOVER OF MARCH 2005 GOAL TO ACHIEVE ANNUAL REVENUES OF $1 BN ONE AMONG TOP 3 BIOTECH COMPANIES BY 2010 STRATEGY INNOVATION-LED STRATEGY LICENSING AND DEVELOPING PROVEN MOLECULES SHOWN POSITIVE SIGNS AND DEMONSTRABLE RESULTS TO ACHIEVE ANNUAL REVENUES OF $1 BILLION

STRATEGY BIOGENETIC INSULIN & MONOCLONAL ANTIBODY LAUNCH FULLY INTEGRATED BUSINESS MODEL BUILD BIO-SIMILAR THERAPEUTIC PROTEIN FRANCHISE

STRATEGIC ALLIANCES WITH 20 COMPANIES AROUND GLOBE AXICORP 2008 ACQUIRE 70% STAKE OF GERMAN PHARMACEUTICAL - MARKETS OF GERMANY & EUROPE IATRICA, 2008 - CO-DEVELOP IMMUNO-CONJUGATES FOR CANCERS AND INFECTIOUS DISEASES DEAKIN UNIVERSITY, 2007 - FOCUS IN BIOTECHNOLOGY & BIOSCIENCES RESEARCH NEOPHARMA, 2007 - Market Biopharmaceuticals in GCC Countries NOBEX CORP USA - ORAL PEPTIDE FOR CARDIOVASCULAR DISEASES - ORAL INSULIN VACCINEX USA CIMAB CUBA

CHALLENGES GENERIC COMPETITION GLOBAL PRICING PRESSURE RISING CLINICAL DEVELOPMENT COSTS GENOMIC MEDICINE SMALLER MARKET SIZE PRODUCT COMMERCIALISATION PARTNERING / GO ALONE DECISIONS PATENT CHALLENGES & DELAY IN REGULATORY APPROVALS APPRECIATION OF INDIAN RUPEE LOSS OF KEY PERSONNEL

INTERNAL- STRENGTH CONSOLIDATED SKILLS IN ENZYMES DERISKED BUSINESS MODEL US FDA CERTIFIED MKT LEADER IN INDIA CORE COMPETENCE IN MOLECULAR BIOLOGY LOW COST CLINICAL RESEARCH DEVELOPMENT OF ORAL INSULIN

INTERNAL - WEAKNESS STATINS- 80% BIOCON TURNOVER (45% REVENUES) MKT REDN FROM $22Bn - $3Bn CAPACITY BUILD UP IN CRO LEAST EXPERTISE IN FINAL STAGE MARKETING

EXTERNAL - OPPORTUNITY $ 82Bn WORTH GLOBAL BBUSTERS FACING PATENT EXPIRY INDIA SHARE OF GLOBAL GENERICS MKT INC TO 33% FROM 4% ENZYMES MKT GROWING AT 6.5% OUTSOURCING TO REDUCE COST INDIA PREFERRED DESTINATION FOR CLINICAL TRIALS ($70Mn-20% Gr) 177 Mn(G) / 45Mn(I) DIABETIC PATIENTS 9Mn CANCER CASES ENTRY OF VENTURE CAPITALISTS

EXTERNAL - THREATS RISK IN DRUG DISCOVERY GENERICS MKT BING OVERCROWDED STRICT IP REGULATOTY LAWS LOW COST CHINESE COMPETITORS INTENSE COMPETITION IN CRO

SWOT ANALYSIS